X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
79
PharmaCompass offers a list of Rivaroxaban API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Rivaroxaban manufacturer or Rivaroxaban supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Rivaroxaban manufacturer or Rivaroxaban supplier.
PharmaCompass also assists you with knowing the Rivaroxaban API Price utilized in the formulation of products. Rivaroxaban API Price is not always fixed or binding as the Rivaroxaban Price is obtained through a variety of data sources. The Rivaroxaban Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Rivaroxaban manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Rivaroxaban, including repackagers and relabelers. The FDA regulates Rivaroxaban manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Rivaroxaban API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Rivaroxaban manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Rivaroxaban supplier is an individual or a company that provides Rivaroxaban active pharmaceutical ingredient (API) or Rivaroxaban finished formulations upon request. The Rivaroxaban suppliers may include Rivaroxaban API manufacturers, exporters, distributors and traders.
click here to find a list of Rivaroxaban suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Rivaroxaban DMF (Drug Master File) is a document detailing the whole manufacturing process of Rivaroxaban active pharmaceutical ingredient (API) in detail. Different forms of Rivaroxaban DMFs exist exist since differing nations have different regulations, such as Rivaroxaban USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Rivaroxaban DMF submitted to regulatory agencies in the US is known as a USDMF. Rivaroxaban USDMF includes data on Rivaroxaban's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Rivaroxaban USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Rivaroxaban suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Rivaroxaban Drug Master File in Japan (Rivaroxaban JDMF) empowers Rivaroxaban API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Rivaroxaban JDMF during the approval evaluation for pharmaceutical products. At the time of Rivaroxaban JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Rivaroxaban suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Rivaroxaban Drug Master File in Korea (Rivaroxaban KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Rivaroxaban. The MFDS reviews the Rivaroxaban KDMF as part of the drug registration process and uses the information provided in the Rivaroxaban KDMF to evaluate the safety and efficacy of the drug.
After submitting a Rivaroxaban KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Rivaroxaban API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Rivaroxaban suppliers with KDMF on PharmaCompass.
A Rivaroxaban CEP of the European Pharmacopoeia monograph is often referred to as a Rivaroxaban Certificate of Suitability (COS). The purpose of a Rivaroxaban CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Rivaroxaban EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Rivaroxaban to their clients by showing that a Rivaroxaban CEP has been issued for it. The manufacturer submits a Rivaroxaban CEP (COS) as part of the market authorization procedure, and it takes on the role of a Rivaroxaban CEP holder for the record. Additionally, the data presented in the Rivaroxaban CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Rivaroxaban DMF.
A Rivaroxaban CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Rivaroxaban CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Rivaroxaban suppliers with CEP (COS) on PharmaCompass.
A Rivaroxaban written confirmation (Rivaroxaban WC) is an official document issued by a regulatory agency to a Rivaroxaban manufacturer, verifying that the manufacturing facility of a Rivaroxaban active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Rivaroxaban APIs or Rivaroxaban finished pharmaceutical products to another nation, regulatory agencies frequently require a Rivaroxaban WC (written confirmation) as part of the regulatory process.
click here to find a list of Rivaroxaban suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Rivaroxaban as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Rivaroxaban API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Rivaroxaban as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Rivaroxaban and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Rivaroxaban NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Rivaroxaban suppliers with NDC on PharmaCompass.
Rivaroxaban Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Rivaroxaban GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Rivaroxaban GMP manufacturer or Rivaroxaban GMP API supplier for your needs.
A Rivaroxaban CoA (Certificate of Analysis) is a formal document that attests to Rivaroxaban's compliance with Rivaroxaban specifications and serves as a tool for batch-level quality control.
Rivaroxaban CoA mostly includes findings from lab analyses of a specific batch. For each Rivaroxaban CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Rivaroxaban may be tested according to a variety of international standards, such as European Pharmacopoeia (Rivaroxaban EP), Rivaroxaban JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Rivaroxaban USP).
Market Place
